Nausea and vomiting caused by anticancer treatments remain significant problems, and are associated with reduced quality of life and decreased anticancer treatment adherence. While there has been much progress made in the research of antiemetic medications, there continues to be barriers preventing nausea and vomiting, of which one is limited patient education.
To help address this, the 2023 MASCC/ESMO Consensus Committee developed an inaugural Patient Antiemetic Guideline Committee with a twofold purpose: to (1) adapt the updated 2023 MASCC evidence-based, clinical guidelines to patient-centered antiemetic guidelines using patient-friendly language and (2) review existing reputable resources/instructions for patients to develop Patient Educational Statements about cancer treatment-related nausea and vomiting prevention that is supported by expert opinion consensus. The patients’ perspectives were included in this work through patient advocate committee involvement, focus group input, and a global pilot survey.
These new resources can help patients and caregivers understand the prevention of nausea and vomiting related to their cancer treatment. To download these free resources, click here.
To read the accompanying scientific publication, click here.
To download the 2023 MASCC/ESMO Antiemetic Guidelines, click here.
